Scarica l'app Stockscreener
50.36
0.45%
-0.23
Dopo l'orario di chiusura:
50.37
0.010
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$50.59
Aprire:
$49.345
Volume 24 ore:
2.16M
Relative Volume:
1.94
Capitalizzazione di mercato:
$4.29B
Reddito:
$170.10M
Utile/perdita netta:
$-153.61M
Rapporto P/E:
-11.27
EPS:
-4.47
Flusso di cassa netto:
$-272.35M
1 W Prestazione:
+2.90%
1M Prestazione:
+11.00%
6M Prestazione:
-9.89%
1 anno Prestazione:
-1.24%
Intervallo 1D:
$47.04
$50.42
Intervallo di 1 settimana:
$46.30
$51.90
Portata 52W:
$43.42
$91.10
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform - Investing.com
CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners - StreetInsider.com
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4%Here's Why - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN
CRSPCRISPR Therapeutics AG Latest Stock News & Market Updates - StockTitan
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average - Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
International Assets Investment Management LLC Invests $1.83 Million in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Capital Advisors Inc. OK - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 7.2%Still a Buy? - MarketBeat
Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock? - MSN
Crispr Therapeutics: Avoid Catching The Falling Knife This Time (Downgrade) (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store? - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Raised to "Sell" at StockNews.com - MarketBeat
Shareholders in CRISPR Therapeutics (NASDAQ:CRSP) are in the red if they invested three years ago - Simply Wall St
Crispr Therapeutics: Poised For A Major Turnaround (NASDAQ:CRSP) - Seeking Alpha
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now - MSN
The Ultimate Biotech Stock to Buy With $50 Right Now - MSN
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - MSN
Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High? - MSN
How the (CRSP) price action is used to our Advantage - Stock Traders Daily
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN
We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth - Yahoo Finance
3 Bargain Stocks to Buy in a Market That's Priced for Perfection - The Motley Fool
Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey
Crispr therapeutics CEO sells shares worth $198,680 By Investing.com - Investing.com Australia
Crispr Therapeutics' general counsel sells $50,398 in shares By Investing.com - Investing.com Australia
Crispr Therapeutics' general counsel sells $50,398 in shares - Investing.com India
CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel Sells $50,398.92 in Stock - MarketBeat
Crispr therapeutics CEO sells shares worth $198,680 - Investing.com
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.9%Here's Why - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.2%Here's Why - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gene Editing Technology Market Is in Huge Demand:Thermo Fisher Scientific, SIGMA ALDRICH, Dharmacon, Cellectics, CRISPR Therapeutics, A – IndiaPolitics.com - IndiaPolitics.com
Is CRISPR Therapeutics Stock a Buy? - Yahoo Finance
2 Biotech Stocks That Are Screaming Buys This Month - Yahoo Finance
Handelsbanken Fonder AB Lowers Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 0.6%Time to Buy? - MarketBeat
Page 6 | CRISPR Therapeutics AG Trade Ideas — CAPITALCOM:CRSP - TradingView
Page 4 | CRISPR Therapeutics AG Trade Ideas — CAPITALCOM:CRSP - TradingView
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.5%Time to Sell? - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - MSN
Gene Editing Tools Market Poised for Massive Growth (2024-2031) - openPR
(CRSP) Trading Signals - Stock Traders Daily
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):